Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 7/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001635 | 0.94 | PTGDR2 (0.34) | IKBKBPTGDR2HTR6CYP2C19KMT2A | |
| SCHEMBL14837115 | 0.89 | HTR6 (0.35) | PTGDR2HTR6CYP2C19KMT2ABRD4 | |
| SCHEMBL2989539 | 0.83 | ENPP3 (0.36) | PTGDR2HTR6CYP2C19BRD4LMNA | |
| SCHEMBL2994911 | 0.80 | LMNA (0.46) | IKBKBPTGDR2HTR6CYP2C19KMT2A | |
| SCHEMBL2986139 | 0.74 | LMNA (0.47) | PTGDR2HTR6CYP2C19KMT2ALMNA | |
| SCHEMBL2995312 | 0.70 | SMN1; SMN2 (0.46) | PTGDR2HTR6CYP2C19KMT2ABRD4 | |
| SCHEMBL2988219 | 0.69 | CDK5 (0.45) | IKBKB | |
| SCHEMBL25422548 | 0.68 | L3MBTL1 (0.41) | IKBKBPTGDR2KMT2ABRD4LMNA | |
| SCHEMBL2993407 | 0.68 | LMNA (0.47) | PTGDR2HTR6CYP2C19KMT2ADRD2 | |
| SCHEMBL30461622 | 0.68 | L3MBTL1 (0.41) | IKBKBPTGDR2KMT2ABRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184790-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184790-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | BAD, PPOX, CASP3 | IKBKB 1393/4885PTGDR2 814/4885HTR6 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.